$33.82
0.511.52%
At close: -
Tools
Free Benzinga Pro Trial
Calendars
Trade Ideas
Short Interest
Comments
Loading...
Sector
Healthcare
Region
US
AUM
107.57M
Fund Score
ALPS Medical Breakthroughs ETF (ARCA:SBIO) Quotes, Forecast and News Summary
ALPS Medical Breakthroughs ETF (ARCA: SBIO) stock price, news, charts, stock research, profile.
| Open | $33.22 |
| High | $34.27 |
| 52 Wk High | $42.73 |
| AUM | 107.57M |
| Dividend | $0.07 |
| Ex-Div Date | Dec 21, 2023 |
| Volume | 4.37K |
| Market Cap | $4.11B |
| Mgmt Fee | 0.5% |
| P/E Ratio | 26.68 |
| Prev. Close | $33.31 |
| Low | $33.22 |
| 52 Wk Low | $30.46 |
| Shares Out | 3.20M |
| Yield | 0.20% |
| Div. Freq | Annual |
| Avg. Volume Daily | 7.15K |
| Beta | 0.88 |
| Avg. Expense Ratio | 0.5% |
| P/B Ratio | 3.71 |
Recent News
FAQ
Q
How do I buy ALPS Medical Breakthroughs ETF (SBIO) stock?
A
You can purchase shares of ALPS Medical Breakthroughs ETF (ARCA:SBIO) through any online brokerage.
Q
Who are ALPS Medical Breakthroughs ETF (SBIO) competitors?
A
There are no as such competitors for ALPS Medical Breakthroughs ETF.
Q
What is the forecast, or price target, for ALPS Medical Breakthroughs ETF (SBIO) stock?
A
There is no analysis for ALPS Medical Breakthroughs ETF to provide a consensus price target.
Q
What is the current price for ALPS Medical Breakthroughs ETF (SBIO)?
A
The stock price for ALPS Medical Breakthroughs ETF (ARCA: SBIO) is $33.82 last updated December 20, 2024 at 8:00 PM EST.
Q
Does ALPS Medical Breakthroughs ETF (SBIO) pay a dividend?
A
A quarterly cash dividend of 0.58 per share of Class A Common Stock. The quarterly cash dividend was payable on December 28, 2017 to stockholders of record on December 21, 2017.
Q
When is ALPS Medical Breakthroughs ETF (ARCA:SBIO) reporting earnings?
A
ALPS Medical Breakthroughs ETF does not have any upcoming earnings scheduled.
Q
Is ALPS Medical Breakthroughs ETF (SBIO) going to split?
A
There is no upcoming split for ALPS Medical Breakthroughs ETF.
| Open | $33.22 |
| High | $34.27 |
| 52 Wk High | $42.73 |
| AUM | 107.57M |
| Dividend | $0.07 |
| Ex-Div Date | Dec 21, 2023 |
| Volume | 4.37K |
| Market Cap | $4.11B |
| Mgmt Fee | 0.5% |
| P/E Ratio | 26.68 |
| Prev. Close | $33.31 |
| Low | $33.22 |
| 52 Wk Low | $30.46 |
| Shares Out | 3.20M |
| Yield | 0.20% |
| Div. Freq | Annual |
| Avg. Volume Daily | 7.15K |
| Beta | 0.88 |
| Avg. Expense Ratio | 0.5% |
| P/B Ratio | 3.71 |
ETF Details
| Sector | Healthcare |
| Category | Mid Performer-Mid Growth |
| Investment Style | Small Cap Growth |
| Fund Inception | Dec 30, 2014 |
| Managers | Charles Perkins Ryan Mischke Andrew Hicks |
| Definition | Most of the stocks in this Equity Fund have average financial performance and average growth potential |
Investment Policy
The fund employs a passive management - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Top ETF Holdings
| Symbol | Name | Share % |
|---|---|---|
| PCVX | Vaxcyte Inc | 5.18% |
| CERE | Cerevel Therapeutics H... | 5.04% |
| VKTX | Viking Therapeutics In... | 4.45% |
| RVMD | Revolution Medicines I... | 4.30% |
| SMMT | Summit Therapeutics Pl... | 4.14% |
| IE | Alkermes Plc | 2.67% |
| AXSM | Axsome Therapeutics, I... | 2.37% |
| CRNX | Crinetics Pharmaceutic... | 2.36% |
| CORT | Corcept Therapeutics I... | 2.13% |
| MRUS | Merus Nv | 2.10% |
Popular Channels
Tools & Features
Partners & Contributors
About Benzinga
© 2024 Benzinga | All Rights Reserved